TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Announced Collaboration with Catalent to Further Expand Thin Film Freezing Applications with a Focus on Biologic Drug Development
Announced Second CRADA Agreement with USAMRIID and Geneva Foundation to Develop Novel Therapies Using Thin Film Freezing to Combat SARS-CoV-2, Ebola, and Marburg Viruses
Initiated Phase 2 Trials of Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder With Interim Data for Each Program Expected Later in 2022
Significant Progress Made in Inhaled Niclosamide Powder Program
Multiple Abstracts Highlighting Applications of Thin Film Freezing Presented at Respiratory Drug Delivery (RDD) Meeting
Conference Call and Webcast Scheduled Today, Wednesday, May 11, 2022 at 4:30 PM ET
FORT WORTH, Texas, May 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the first quarter of 2022 and provided an update on recent corporate and clinical developments. The Company will discuss the highlights on a conference call and webcast, scheduled for today, Wednesday, May 11, 2022, at 4:30 PM ET.
“During the first quarter, we made solid progress in expanding existing collaborations and forging new partnerships,” said Glenn Mattes, CEO of TFF Pharmaceuticals. “Most notably, we announced a strategic collaboration with Catalent that will enable their customers to gain access to our Thin Film Freezing technology, with an emphasis on applications in biologic drug development. We also expanded our activities with USAMRIID and the Geneva Foundation by signing a second CRADA agreement that will utilize our Thin Film Freezing technology to optimize the formulation of new, development-stage therapeutics aimed at combating exceptionally dangerous viruses, including SARS-CoV-2, Ebola, and Marburg. Based upon the robust pace of our ongoing partnering discussions, we remain confident that 2022 will see TFF pharmaceuticals enter into new collaborations while expanding many of our existing partnerships.
“With respect to our pipeline development, we made considerable progress across several programs during the quarter. We initiated Phase 2 studies for our Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder, and we anticipate interim readouts for both trials later in the year. With each program having the potential to meaningfully advance the current standard of care in their respective indications, we believe positive readouts are likely to attract significant partnership interest.
The Inhaled Niclosamide Powder program has also made important progress. In April, we announced positive safety and pharmacokinetic data from a Phase 1 study, demonstrating that Niclosamide Inhalation Powder was well tolerated with no serious adverse events across all subject cohorts. We believe the Niclosamide program is yet another example of how Thin Film Freezing technology can be successfully applied in the clinic to deliver efficacious levels of drug more safely to patients.
“In early May, we were pleased to announce that Dr. Bill Williams, co-inventor of the Thin Film Freezing technology, and several of his colleagues from the University of Texas at Austin presented five abstracts at this year’s Respiratory Drug Delivery meeting related to applications of Thin Film Freezing. We believe this body of research underscores the unique and versatile nature of Thin Film Freezing technology and provides us with even more confidence that the pharmaceutical applications of our technology platform will only continue to grow over time.
“As our platform continues to expand, TFF is also making the appropriate level of investment to recruit exceptional talent to help manage this growth. During the quarter, we announced the appointment of Anthony Hickey, Ph.D. as Chief Scientific Officer and Brandi Roberts to our Board of Directors. We also made senior level appointments in key areas of our business, including product manufacturing, government and strategic initiatives, and regulatory affairs.
“The advancement of our internal pipeline candidates such as Inhaled Voriconazole and Tacrolimus Powder programs, coupled with the robust pace of ongoing partnering activity, strengthens our belief that our continued investment in Thin Film Freezing will translate into significant commercial success and value for our shareholders.”
Conference Call and Webcast Information
The Company will host a conference call today, Wednesday, May 11, 2022, at 4:30 PM, Eastern Time, to review the clinical, corporate and financial highlights. To participate in the conference call, please dial the following numbers prior to the start of the call:
Domestic Dial-In Number: Toll-Free: 1-844-825-9789
International Dial-In Number: 1-412-317-5180
Conference ID: 10166801
The call will also be broadcast live over the Web and can be accessed on TFF Pharmaceuticals’ Website, https://tffpharma.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1546904&tp_key=ca1cf4dc0b
Please access the Company's website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software. The conference call will also be available for replay for one month on the Company's website in the Events Calendar of the Investors section.
Recent Clinical and Corporate Highlights:
For the quarter ended March 31, 2022, compared to quarter ended March 31, 2021
ABOUT TFF PHARMACEUTICALS’ THIN FILM FREEZING TECHNOLOGY PLATFORM
ABOUT TFF PHARMACEUTICALS
Investor Relations Contact:
Corey Davis, Ph.D.
1 Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013 May;51(4):361-70. doi: 10.3109/13693786.2012.738312. Epub 2012 Dec 4. PMID: 23210682. Accessed November 5, 2021.
Aligning Business Productivity Tools with the Modern Workforce
Zero Trust - Why Micro-Segmentation is Mandatory
Presentation Details TBA